Advertisement

 

 

In vitro susceptibility of methicillin-resistant Staphylococcus aureus isolates from skin and soft tissue infections to vancomycin, daptomycin, linezolid, and tedizolid.

In vitro susceptibility of methicillin-resistant Staphylococcus aureus isolates from skin and soft tissue infections to vancomycin, daptomycin, linezolid, and tedizolid.
Author Information (click to view)

Vanegas Múnera JM, Ocampo Ríos AM, Urrego DM, Jiménez Quiceno JN,


Vanegas Múnera JM, Ocampo Ríos AM, Urrego DM, Jiménez Quiceno JN, (click to view)

Vanegas Múnera JM, Ocampo Ríos AM, Urrego DM, Jiménez Quiceno JN,

Advertisement

The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 2017 04 19() pii S1413-8670(16)30581-5
Abstract
INTRODUCTION
Treatment of multidrug-resistant Gram-positive infections caused by Staphylococcus aureus remains as a clinical challenge due to emergence of new resistance mechanisms. Tedizolid is a next-generation oxazolidinone, recently approved for skin and soft tissues infections. We conducted a study to determine in vitro susceptibility to vancomycin, daptomycin, linezolid, and tedizolid in MRSA clinical isolates from adult patients with skin and soft tissue infections.

MATERIAL AND METHODS
Methicillin-resistant S. aureus isolates were collected in three tertiary-care hospitals of Medellin, Colombia, from February 2008 to June 2010 as part of a previous study. Clinical characteristics were assessed by medical records and MIC values were determined by Epsilometer test. Genotypic analysis included spa typing, MLST, and SCCmec typing.

RESULTS
A total of 150 MRSA isolates were evaluated and tedizolid MIC values obtained showed higher in vitro activity than other antimicrobials, with MIC values ranging from 0.13μg/mL to 0.75μg/mL and lower values of MIC50 and MIC90 (0.38μg/mL and 0.5μg/mL). In contrast, vancomycin and linezolid had higher MIC values, which ranged from 0.5μg/mL to 2.0μg/mL and from 0.38μg/mL to 4.0μg/mL, respectively. Tedizolid MICs were 2- to 5-fold lower than those of linezolid. Clinical characteristics showed high previous antimicrobial use and hospitalization history. The majority of the strains belong to the CC8 harboring the SCCmec IVc and were associated with the spa t1610 (29.33%, n=44).

CONCLUSION
In vitro effectiveness of tedizolid was superior for isolates from skin and soft tissue infections in comparison with the other antibiotics evaluated. In addition, tedizolid was less toxic, presented good bioavailability, dosed once daily, and requiring no dosage adjustment. Therefore, tedizolid is a promising alternative for the treatment of infections caused by MRSA.

Submit a Comment

Your email address will not be published. Required fields are marked *

4 × 5 =

[ HIDE/SHOW ]